AlzChem Group AG (ETR:ACT)
Germany · Delayed Price · Currency is EUR | Market Cap | 1.79B +43.0% |
| Revenue (ttm) | 581.10M +4.0% |
| Net Income | 66.82M +18.3% |
| EPS | 6.61 +18.9% |
| Shares Out | 10.12M |
| PE Ratio | 26.76 |
| Forward PE | 25.22 |
| Dividend | 2.10 (1.19%) |
| Ex-Dividend Date | May 6, 2026 |
| Volume | 30,248 |
| Open | 175.80 |
| Previous Close | 176.90 |
| Day's Range | 175.20 - 191.30 |
| 52-Week Range | 121.80 - 191.30 |
| Beta | 0.37 |
| Analysts | Strong Buy |
| Price Target | 192.07 (+1.68%) |
| Earnings Date | Apr 30, 2026 |
About AlzChem Group AG
AlzChem Group AG, together with its subsidiaries, develops, produces, and markets a range of chemical specialties in Germany, European Union, rest of Europe, Asia, NAFTA region, and internationally. It operates through three segments: Specialty Chemicals, Basics & Intermediates, and Other & Holding. The Specialty Chemicals segment sells specialty chemical products that are used in the chemical, food, animal feed, defence technology, and renewable energies industries. This segment manufactures composite materials and adhesives, as well as silico... [Read more]
Financial Performance
In 2025, AlzChem Group AG's revenue was 575.05 million, an increase of 2.06% compared to the previous year's 563.44 million. Earnings were 63.46 million, an increase of 17.35%.
Financial StatementsNews
AlzChem price target raised to EUR 200 from EUR 195 at Jefferies
Jefferies raised the firm’s price target on AlzChem (ALZCF) to EUR 200 from EUR 195 and keeps a Buy rating on the shares. The firm views the company’s earnings report…
AlzChem Group AG Earnings Call Transcript: Q1 2026
Revenue and profitability grew strongly in Q1 2026, led by specialty ingredients and robust demand in nutrition and defense. Major CapEx projects are on track, and full-year guidance is confirmed despite some cost pressures, with positive cash flow and a strong equity position.
AlzChem Group AG Slides: Q1 2026
AlzChem Group AG has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 30, 2026.
AlzChem Group AG Earnings release: Q1 2026
AlzChem Group AG released its Q1 2026 earnings on April 30, 2026, summarizing the period's financial results.
AlzChem Group AG Quarterly report: Q1 2026
AlzChem Group AG has published its Q1 2026 quarterly earnings report on April 30, 2026.
AlzChem price target raised to EUR 197 from EUR 185 at Berenberg
Berenberg analyst Gerhard Orgonas raised the firm’s price target on AlzChem (ALZCF) to EUR 197 from EUR 185 and keeps a Buy rating on the shares.
AlzChem price target raised to EUR 195 from EUR 190 at Jefferies
Jefferies raised the firm’s price target on AlzChem (ALZCF) to EUR 195 from EUR 190 and keeps a Buy rating on the shares. The company’s Q4 report confirmed its continued…
AlzChem Group AG Earnings Call Transcript: H2 2025
Sales and EBITDA grew year-over-year, driven by specialty chemicals and strong creatine demand, with record margins and robust cash flow. Major investments in creatine and defense capacity set the stage for double-digit growth from 2027.
AlzChem Group AG Earnings release: H2 2025
AlzChem Group AG released its H2 2025 earnings on February 27, 2026, summarizing the period's financial results.
AlzChem Group AG Annual report: H2 2025
AlzChem Group AG has published its H2 2025 annual report on February 27, 2026.
AlzChem Group AG Slides: H2 2025
AlzChem Group AG has posted slides in relation to its H2 2025 quarterly earnings report, which was published on February 27, 2026.
AlzChem Group AG Slides: Company presentation
AlzChem Group AG has posted slides in relation to its latest quarterly earnings report, which was published on February 27, 2026.
AlzChem initiated with a Buy at Jefferies
Jefferies initiated coverage of AlzChem (ALZCF) with a Buy rating and EUR 190 price target The firm is positive on the company’s unique production platform and leading niche, which positions…
AlzChem Group AG Earnings Call Transcript: Q3 2025
Specialty chemicals drove strong Q3 and nine-month growth, with EBITDA up 12% and margin at 20.3%. Capacity expansions, new product launches, and a robust outlook for full-year sales and earnings highlight continued momentum, despite FX and energy cost risks.
AlzChem Group AG Quarterly report: Q3 2025
AlzChem Group AG has published its Q3 2025 quarterly earnings report on October 30, 2025.
AlzChem Group AG Slides: Q3 2025
AlzChem Group AG has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on October 30, 2025.
AlzChem Group AG Earnings Call Transcript: Q2 2025
Sales and EBITDA grew in H1 2025, led by Specialty Chemicals, especially creatine and custom synthesis. CapEx and customer grants support major expansions, while risks include energy costs, Chinese competition, and regulatory uncertainty. Guidance for 2025 is confirmed.
AlzChem Group AG Quarterly report: Q2 2025
AlzChem Group AG has published its Q2 2025 quarterly earnings report on July 30, 2025.
AlzChem Group AG Slides: Q2 2025
AlzChem Group AG has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on July 30, 2025.